These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 35977397)

  • 1. Treatment of secondary hyperparathyroidism in non-dialysis CKD: an appraisal 2022s.
    Ketteler M; Bover J; Mazzaferro S
    Nephrol Dial Transplant; 2023 May; 38(6):1397-1404. PubMed ID: 35977397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin D and Secondary Hyperparathyroidism in Chronic Kidney Disease: A Critical Appraisal of the Past, Present, and the Future.
    Brandenburg V; Ketteler M
    Nutrients; 2022 Jul; 14(15):. PubMed ID: 35893866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Where are we now? Emerging opportunities and challenges in the management of secondary hyperparathyroidism in patients with non-dialysis chronic kidney disease.
    Ketteler M; Ambühl P
    J Nephrol; 2021 Oct; 34(5):1405-1418. PubMed ID: 34170509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended-release calcifediol in stage 3-4 chronic kidney disease: a new therapy for the treatment of secondary hyperparathyroidism associated with hypovitaminosis D.
    Cozzolino M; Minghetti P; Navarra P
    J Nephrol; 2022 Apr; 35(3):863-873. PubMed ID: 34626363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Cinacalcet and Etelcalcetide on Bone Mineral and Cardiovascular Disease in Dialysis Patients.
    Bernardor J; De Mul A; Bacchetta J; Schmitt CP
    Curr Osteoporos Rep; 2023 Apr; 21(2):193-204. PubMed ID: 36848027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary hyperparathyroidism among Nigerians with chronic kidney disease.
    Gimba ZM; Abene EE; Agbaji OOO; Agaba EI
    Afr Health Sci; 2018 Jun; 18(2):446-457. PubMed ID: 30602972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating extended-release calcifediol as a treatment option for chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Cozzolino M; Ketteler M
    Expert Opin Pharmacother; 2019 Dec; 20(17):2081-2093. PubMed ID: 31675257
    [No Abstract]   [Full Text] [Related]  

  • 8. Secondary hyperparathyroidism in chronic kidney disease: pathomechanism and current treatment possibilities.
    Rodzoń-Norwicz M; Norwicz S; Sowa-Kućma M; Gala-Błądzińska A
    Endokrynol Pol; 2023; 74(5):490-498. PubMed ID: 37902013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Extended release calcifediol and paricalcitol in the treatment of secondary hyperparathyroidism: a network meta-analysis of indirect comparison].
    Franchi M; Galassi A; Corrao G
    G Ital Nefrol; 2023 Feb; 40(1):. PubMed ID: 36883925
    [No Abstract]   [Full Text] [Related]  

  • 10. Paricalcitol and Extended-Release Calcifediol for Treatment of Secondary Hyperparathyroidism in Non-Dialysis Chronic Kidney Disease: Results From a Network Meta-Analysis.
    Franchi M; Gunnarsson J; Gonzales-Parra E; Ferreira A; Ström O; Corrao G
    J Clin Endocrinol Metab; 2023 Oct; 108(11):e1424-e1432. PubMed ID: 37235771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Independent effects of secondary hyperparathyroidism and hyperphosphataemia on chronic kidney disease progression and cardiovascular events: an analysis from the NEFRONA cohort.
    Bozic M; Diaz-Tocados JM; Bermudez-Lopez M; Forné C; Martinez C; Fernandez E; Valdivielso JM
    Nephrol Dial Transplant; 2022 Mar; 37(4):663-672. PubMed ID: 34021359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological Management of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease.
    Salam SN; Khwaja A; Wilkie ME
    Drugs; 2016 May; 76(8):841-52. PubMed ID: 27142279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease.
    Strugnell SA; Sprague SM; Ashfaq A; Petkovich M; Bishop CW
    Am J Nephrol; 2019; 49(4):284-293. PubMed ID: 30878999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fractures in patients with CKD-diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation.
    Pimentel A; Ureña-Torres P; Zillikens MC; Bover J; Cohen-Solal M
    Kidney Int; 2017 Dec; 92(6):1343-1355. PubMed ID: 28964571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mineral Bone Disorders in Kidney Disease Patients: The Ever-Current Topic.
    Hu L; Napoletano A; Provenzano M; Garofalo C; Bini C; Comai G; La Manna G
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness of extended-release calcifediol versus paricalcitol for the treatment of secondary hyperparathyroidism in stage 3-4 CKD.
    Kalantar-Zadeh K; Hollenbeak CS; Arguello R; Snyder S; Ashfaq A
    J Med Econ; 2020 Mar; 23(3):308-315. PubMed ID: 31726882
    [No Abstract]   [Full Text] [Related]  

  • 18. Cinacalcet studies in pediatric subjects with secondary hyperparathyroidism receiving dialysis.
    Warady BA; Ng E; Bloss L; Mo M; Schaefer F; Bacchetta J
    Pediatr Nephrol; 2020 Sep; 35(9):1679-1697. PubMed ID: 32367309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of hyperphosphatemia: the dangers of aiming for normal PTH levels.
    Haffner D; Leifheit-Nestler M
    Pediatr Nephrol; 2020 Mar; 35(3):485-491. PubMed ID: 31823044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of hyperphosphatemia: the dangers of high PTH levels.
    Bacchetta J
    Pediatr Nephrol; 2020 Mar; 35(3):493-500. PubMed ID: 31696357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.